Showing results (61-70 of 662) with videos related to
Sort By:
Pageof 67
Journal of Hepatology|June 18, 2016
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practiceParambir S Dulai, Claude B Sirlin, Rohit LoombaAdvances in Therapy|November 19, 2009
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current statusLance L Stein, Mamie H Dong, Rohit LoombaCell Metabolism|April 12, 2024
New and emerging treatments for metabolic dysfunction-associated steatohepatitisMonica A Tincopa, Quentin M Anstee, Rohit LoombaAmerican Journal of Therapeutics|April 27, 2011
Ideal antiplatelet therapy for coronary artery disease: focus on adenosine diphosphate receptor inhibitorsSuraj Chandrasekar, Rohit Loomba, Parinda Shah, et al.Cell|May 14, 2021
Mechanisms and disease consequences of nonalcoholic fatty liver diseaseRohit Loomba, Scott L Friedman, Gerald I ShulmanAnnals of Laboratory Medicine|August 25, 2020
Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver DiseasesNobuharu Tamaki, Masayuki Kurosaki, Rohit Loomba, et al.Nature Reviews. Gastroenterology & Hepatology|September 2, 2015
Caring for children with NAFLD and navigating their care into adulthoodAli A Mencin, Rohit Loomba, Joel E LavineAnnals of Hepatology|October 24, 2025
Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASHBradley Jermy, Jack Brownrigg, Pavel Strnad, et al.Clinics in Liver Disease|May 16, 2026
Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated SteatohepatitisAngelo Armandi, Elisabetta Bugianesi, Rohit Loomba, et al.Journal of Diabetes and Its Complications|January 15, 2013
Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetesIliana Doycheva, Niraj Patel, Michael Peterson, et al.Pageof 67